title: Vascular response to overlapping everolimus-eluting stents. - Comparison with paclitaxel-eluting stents -.
abstract: BACKGROUND
  Overlapping drug-eluting stents might be associated with an adverse vessel response because of increased drug/polymer toxicity and lesion rigidity.
  
  
  RESULTS
  Lesions treated with overlapping everolimus- (EES=36) or paclitaxel-eluting stents (PES=38) were analyzed for 8-9-months by 3-dimensional intravascular ultrasound. EES were associated with significantly greater neointimal suppression in the single-strut regions than PES, with a similar trend in the overlap region. PES had significant vessel expansion in all regions, whereas there were no changes with EES. Neither stent fracture nor late incomplete stent apposition (LISA) in the overlap region was observed.
  
  
  CONCLUSIONS
  Overlapping EES appears to be effective without vessel expansion, stent fracture or LISA for up to 8-9 months.
authors.affiliation: Center for Research in Cardiovascular Interventions, Stanford University, CA 94305-5637, USA.
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Otake
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Honda
authors.forename: Masao
authors.initials: M
authors.lastname: Yamasaki
authors.forename: Ichizo
authors.initials: I
authors.lastname: Tsujino
authors.forename: Takao
authors.initials: T
authors.lastname: Shimohama
authors.forename: Ryota
authors.initials: R
authors.lastname: Sakurai
authors.forename: Takao
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Waseda
authors.forename: Junya
authors.initials: J
authors.lastname: Ako
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Fitzgerald
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D003920:Diabetes Mellitus / Q000000981:diagnostic imaging / Q000628:therapy; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006949:Hyperlipidemias / Q000000981:diagnostic imaging / Q000628:therapy; D006973:Hypertension / Q000000981:diagnostic imaging / Q000628:therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000494:pharmacology*; D012189:Retrospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D018084:Ultrasonography, Interventional
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus